Suppr超能文献

分子机制与大麻素药理学

Molecular Mechanism and Cannabinoid Pharmacology.

作者信息

Schurman Lesley D, Lu Dai, Kendall Debra A, Howlett Allyn C, Lichtman Aron H

机构信息

Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.

Rangel College of Pharmacy, Health Science Center, Texas A&M University, Kingsville, TX, USA.

出版信息

Handb Exp Pharmacol. 2020;258:323-353. doi: 10.1007/164_2019_298.

Abstract

Since antiquity, Cannabis has provoked enormous intrigue for its potential medicinal properties as well as for its unique pharmacological effects. The elucidation of its major cannabinoid constituents, Δ-tetrahydrocannabinol (THC) and cannabidiol (CBD), led to the synthesis of new cannabinoids (termed synthetic cannabinoids) to understand the mechanisms underlying the pharmacology of Cannabis. These pharmacological tools were instrumental in the ultimate discovery of the endogenous cannabinoid system, which consists of CB and CB cannabinoid receptors and endogenously produced ligands (endocannabinoids), which bind and activate both cannabinoid receptors. CB receptors mediate the cannabimimetic effects of THC and are highly expressed on presynaptic neurons in the nervous system, where they modulate neurotransmitter release. In contrast, CB receptors are primarily expressed on immune cells. The endocannabinoids are tightly regulated by biosynthetic and hydrolytic enzymes. Accordingly, the endocannabinoid system plays a modulatory role in many physiological processes, thereby generating many promising therapeutic targets. An unintended consequence of this research was the emergence of synthetic cannabinoids sold for human consumption to circumvent federal laws banning Cannabis use. Here, we describe research that led to the discovery of the endogenous cannabinoid system and show how knowledge of this system benefitted as well as unintentionally harmed human health.

摘要

自古以来,大麻因其潜在的药用特性以及独特的药理作用引发了巨大的关注。对其主要大麻素成分Δ-四氢大麻酚(THC)和大麻二酚(CBD)的阐明,促使人们合成了新的大麻素(称为合成大麻素),以了解大麻药理学背后的机制。这些药理学工具对于最终发现内源性大麻素系统起到了重要作用,该系统由CB1和CB2大麻素受体以及内源性产生的配体(内源性大麻素)组成,这些配体能够结合并激活两种大麻素受体。CB1受体介导THC的拟大麻效应,在神经系统的突触前神经元上高度表达,在那里它们调节神经递质的释放。相比之下,CB2受体主要在免疫细胞上表达。内源性大麻素受到生物合成和水解酶的严格调控。因此,内源性大麻素系统在许多生理过程中发挥调节作用,从而产生了许多有前景的治疗靶点。这项研究的一个意外后果是出现了供人类消费的合成大麻素,以规避联邦法律对大麻使用的禁令。在此,我们描述了导致内源性大麻素系统发现的研究,并展示了对该系统的了解如何既有益于人类健康,又无意中对其造成了伤害。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b94/8637936/8f6b8050816d/nihms-1753461-f0001.jpg

相似文献

1
Molecular Mechanism and Cannabinoid Pharmacology.分子机制与大麻素药理学
Handb Exp Pharmacol. 2020;258:323-353. doi: 10.1007/164_2019_298.
3
Pharmacological actions of cannabinoids.大麻素的药理作用。
Handb Exp Pharmacol. 2005(168):1-51. doi: 10.1007/3-540-26573-2_1.
7
An Introduction to the Endogenous Cannabinoid System.内源性大麻素系统简介。
Biol Psychiatry. 2016 Apr 1;79(7):516-25. doi: 10.1016/j.biopsych.2015.07.028. Epub 2015 Oct 30.

引用本文的文献

2
Cannabinoids as Multitarget Drugs for the Treatment of Autoimmunity in Glaucoma.大麻素作为治疗青光眼自身免疫性疾病的多靶点药物。
ACS Pharmacol Transl Sci. 2025 Mar 26;8(4):932-950. doi: 10.1021/acsptsci.4c00583. eCollection 2025 Apr 11.

本文引用的文献

2
Medical Cannabis: A plurimillennial history of an evergreen.医用大麻:一种常绿植物的千年级历史。
J Cell Physiol. 2019 Jun;234(6):8342-8351. doi: 10.1002/jcp.27725. Epub 2018 Nov 11.
6
New approaches and challenges to targeting the endocannabinoid system.靶向内源性大麻素系统的新方法与挑战
Nat Rev Drug Discov. 2018 Sep;17(9):623-639. doi: 10.1038/nrd.2018.115. Epub 2018 Aug 17.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验